Compugen (CGEN) Change in Accured Expenses (2009 - 2018)

Compugen (CGEN) reported Change in Accured Expenses of $1.1 million for Q4 2018, up 40.34% sequentially from $776000.0 in Q4 2010.

Compugen (CGEN) Change in Accured Expenses (2009 - 2018) Analysis & Trends

Compugen (CGEN) has 3 years of Change in Accured Expenses data on file, last reported at $1.1 million in Q4 2018.

For the quarter ending Q4 2018, Change in Accured Expenses changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2018 stood at $1.1 million (changed N/A YoY), and the FY2025 full-year result was -$109000.0, up 78.33% from the prior year.
Change in Accured Expenses grew to $1.1 million in Q4 2018, from $776000.0 in the prior quarter.
In the past five years, Change in Accured Expenses ranged from a high of $1.1 million in Q4 2018 to a low of $1.1 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Accured Expenses (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	1.13 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-16.82 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	23.10 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	107.70 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-16.74 Mn
10	Compugen	221.26 Mn	129.51 Mn	352,000.00	-

Download Data